128 related articles for article (PubMed ID: 14976814)
1. [Long-acting insulin analog, glargine, in the treatment of type 1 diabetes].
Tuomi T
Duodecim; 2004; 120(1):88-92. PubMed ID: 14976814
[No Abstract] [Full Text] [Related]
2. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
[No Abstract] [Full Text] [Related]
4. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
Tan CY; Wilson DM; Buckingham B
Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
[TBL] [Abstract][Full Text] [Related]
5. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
Al Shamsi AM
Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
[No Abstract] [Full Text] [Related]
6. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
7. Current perspective in insulin therapy in the management of diabetes mellitus.
Garg MK
J Indian Med Assoc; 2002 Mar; 100(3):194-5, 202. PubMed ID: 12408284
[TBL] [Abstract][Full Text] [Related]
8. Insulin therapy in type 2 diabetes.
Davis T; Edelman SV
Med Clin North Am; 2004 Jul; 88(4):865-95, x. PubMed ID: 15308383
[TBL] [Abstract][Full Text] [Related]
9. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
10. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
12. [Insulin pump in the treatment of adult age diabetes].
Sane T; Tulokas T; Nikkanen P; Heikkilä P; Huttunen E; Niskanen L
Duodecim; 2005; 121(8):839-45. PubMed ID: 15931827
[No Abstract] [Full Text] [Related]
13. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.
Kiess W; Raile K; Galler A; Kapellen T
Diabetes Care; 2004 Oct; 27(10):2567-8. PubMed ID: 15451944
[No Abstract] [Full Text] [Related]
14. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
15. [Novel insulin products and delivery methods].
Sipilä I; Saukkonen T
Duodecim; 2004; 120(9):1167-72. PubMed ID: 15232860
[No Abstract] [Full Text] [Related]
16. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
17. [A new long-acting insulin analog. "Fewer hypoglycemias observed"].
Gallwitz B
MMW Fortschr Med; 2004 Jan; 146(3-4):47. PubMed ID: 15035450
[No Abstract] [Full Text] [Related]
18. Insulin pump therapy.
Page C
Tenn Med; 2000 Nov; 93(11):410-4. PubMed ID: 11077887
[No Abstract] [Full Text] [Related]
19. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
20. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
